CADTH Canadian Drug Expert Committee recommendation : indication: for the treatment of major depressive disorder in adults. Esketamine (Spravato -- Janssen inc.) / CADTH Canadian Drug Expert Committee.

Format:

Book

Author/Creator:

CADTH Canadian Drug Expert Committee, author, issuing body.

Language:

English

Subjects (All):

Antidepressants.

Cost effectiveness.

Physical Description:

1 online resource (9 pages)

Edition:

First edition.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2020.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that esketamine not be reimbursed for the treatment of MDD in adults. The results of two four-week randomized controlled trials (RCTs) (TRD3001 and TRD3002) and one randomized withdrawal study (TRD3003) did not demonstrate a consistent statistically significant benefit with esketamine in combination with a newly initiated oral antidepressant compared with placebo in combination with a newly initiated oral antidepressant, in the indicated population.

Notes:

Description based on publisher supplied metadata and other sources.